Daniel Tripa

Daniel Tripa, MBA, currently serves as VP of Finance for Biogen in the Intercontinental Region, contributing to the company's reported total revenue of $9.7 billion for Full Year 2024. Prior to joining Biogen in May 2025, Daniel held various significant roles at AstraZeneca, including Head of FP&A and Global Rare Disease TA Finance, where the division reported an 16% revenue growth and $8.8 billion in total sales for Full Year 2024. As Chief Financial Officer and Interim Country President in Brazil, Daniel played a pivotal role in noteworthy agreements such as a landmark COVID vaccine deal. Daniel's earlier experience at GSK includes serving as Chief Financial Officer for Turkey Pharmaceuticals, overseeing substantial sales growth, and holding multiple finance roles focused on global R&D investments and consumer healthcare. Daniel earned an MBA and a Bachelor's degree in Business Administration from the University of Lisbon.